Search research articles
Contact Us
Filters
Showing results (101-110 of 227) with videos related to
Page
of 23
Sort By:
Leukemia & Lymphoma
|
October 22, 2013
Up-regulation of RUNX2 in acute myeloid leukemia in a patient with an inherent RUNX2 haploinsufficiency and cleidocranial dysplasia
Dominik Schnerch, Ekkehart Lausch, Heiko Becker, et al.
Journal of Medical Economics
|
January 4, 2021
Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany
Tilman Hans Steinmetz, Moushmi Singh, Andrea Lebioda, et al.
European Journal of Haematology
|
September 9, 2017
The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies
Christine Greil, Gabriele Ihorst, Felix Gaiser, et al.
Oncotarget
|
July 5, 2016
Suppression of APC/CCdh1 has subtype specific biological effects in acute myeloid leukemia
Daniel Ewerth, Andrea Schmidts, Manuel Hein, et al.
Haematologica
|
August 2, 2016
Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores
Monika Engelhardt, Sandra Maria Dold, Gabriele Ihorst, et al.
The Oncologist
|
August 2, 2006
Primary (AL) amyloidosis in plasma cell disorders
Antonia M S Müller, Annette Geibel, Hartmut P H Neumann, et al.
Leukemia & Lymphoma
|
October 31, 2017
Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule
Christine Greil, Gabriele Ihorst, Chrissoula Kiote-Schmidt, et al.
Leukemia & Lymphoma
|
January 14, 2017
Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers
Christine Greil, Chrissoula Kiote-Schmidt, Geertje Fink, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 26, 2017
Cast Nephropathy and Deceptively Low Absolute Serum Free Light Chain Levels: Resolution of a Challenging Case and Systematic Review of the Literature
Michael P Rassner, Maximilian Seidl, Ulrich Salzer, et al.
Plos One
|
November 14, 2013
Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies
Julia Schueler, Dagmar Wider, Kerstin Klingner, et al.
Page
of 23
Search research articles
Search
Showing results (101-110 of 227) with videos related to
Sort By:
Page
of 23
Leukemia & Lymphoma
|
October 22, 2013
Up-regulation of RUNX2 in acute myeloid leukemia in a patient with an inherent RUNX2 haploinsufficiency and cleidocranial dysplasia
Dominik Schnerch, Ekkehart Lausch, Heiko Becker, et al.
Journal of Medical Economics
|
January 4, 2021
Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany
Tilman Hans Steinmetz, Moushmi Singh, Andrea Lebioda, et al.
European Journal of Haematology
|
September 9, 2017
The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies
Christine Greil, Gabriele Ihorst, Felix Gaiser, et al.
Oncotarget
|
July 5, 2016
Suppression of APC/CCdh1 has subtype specific biological effects in acute myeloid leukemia
Daniel Ewerth, Andrea Schmidts, Manuel Hein, et al.
Haematologica
|
August 2, 2016
Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores
Monika Engelhardt, Sandra Maria Dold, Gabriele Ihorst, et al.
The Oncologist
|
August 2, 2006
Primary (AL) amyloidosis in plasma cell disorders
Antonia M S Müller, Annette Geibel, Hartmut P H Neumann, et al.
Leukemia & Lymphoma
|
October 31, 2017
Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule
Christine Greil, Gabriele Ihorst, Chrissoula Kiote-Schmidt, et al.
Leukemia & Lymphoma
|
January 14, 2017
Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers
Christine Greil, Chrissoula Kiote-Schmidt, Geertje Fink, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 26, 2017
Cast Nephropathy and Deceptively Low Absolute Serum Free Light Chain Levels: Resolution of a Challenging Case and Systematic Review of the Literature
Michael P Rassner, Maximilian Seidl, Ulrich Salzer, et al.
Plos One
|
November 14, 2013
Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies
Julia Schueler, Dagmar Wider, Kerstin Klingner, et al.
Page
of 23